Breo Ellipta is a daily inhaler for asthma and COPD. It has two medicines: a steroid that calms swelling in the airways and another that helps the airways stay open. It is used once a day to prevent symptoms, not as a rescue inhaler during an attack.
Every report comes from a Lived member, sent anonymously.
Have you tried Breo Ellipta (Fluticasone Furoate / Vilanterol) for Asthma?
Breo Ellipta is a once-a-day prescription inhaler that combines two medicines: fluticasone furoate, an inhaled corticosteroid (steroid), and vilanterol, a long-acting bronchodilator. It is approved as maintenance treatment, meaning it is used every day to keep symptoms under control, for adults with chronic obstructive pulmonary disease (COPD) and for people aged 5 and older with asthma. An unbranded version sold as Fluticasone Furoate/Vilanterol Ellipta contains the same ingredients in the same device. Breo is not a rescue inhaler. It does not relieve a sudden attack of wheezing or breathlessness, so anyone using it also needs a separate short-acting rescue inhaler, such as albuterol, for those moments.
Asthma and COPD both involve airways that are inflamed and tend to narrow. The two ingredients in Breo work on these problems in different ways. Fluticasone furoate is a steroid that calms inflammation in the airway lining over time, which makes the airways less reactive and helps prevent flare-ups. It acts mainly in the lungs, so the amount reaching the rest of the body is much lower than with steroid tablets, though not zero. Vilanterol belongs to a group called long-acting beta2-agonists, or LABAs. It relaxes the muscle wrapped around the airways so they stay more open, and its effect lasts long enough that a single daily dose is enough. In asthma, a LABA is only used together with an inhaled steroid: on its own, a LABA has been linked to more serious asthma attacks, while the combination has not shown that increased risk in large studies.
Breo is a dry powder inhaled through the mouth from the Ellipta inhaler. Each dose is one inhalation, taken once a day at about the same time. Technique matters for getting the medicine into the lungs, so it helps to practice in front of a pharmacist or clinician and to follow the instructions that come with the inhaler. A forgotten dose can be taken when remembered, unless the next one is almost due. Using it more than once in 24 hours, or doubling up after a missed dose or a bad day, adds risk without adding benefit. The strengths differ by steroid amount (the vilanterol dose is the same in each): 100/25 is the strength for COPD, adults with asthma may use 100/25 or 200/25, teens 12 to 17 use 100/25, and children 5 to 11 use 50/25. After each dose, rinse your mouth with water and spit it out, which lowers the risk of a yeast infection in the mouth (thrush). The inhaler should stay sealed in its foil tray until first use and be thrown away 6 weeks after the tray is opened or when the counter reads 0, whichever comes first.
The most common side effects are cold-like symptoms such as a stuffy or runny nose and sore throat, headache, hoarseness, cough and oral thrush, which shows up as white patches or soreness in the mouth or throat. Thrush is treatable and is much less likely with mouth rinsing after each dose. Back or joint pain can also occur, particularly in people with COPD. People with COPD who use Breo have a higher risk of pneumonia than those using a bronchodilator alone, and some of these cases have been serious. Because pneumonia can look like a COPD flare, fever, chills, a change in the color of mucus or breathing that is worse than usual should be reported to the care team promptly. The vilanterol component can cause a fast, pounding or irregular heartbeat, chest pain, tremor or nervousness; these also call for a prompt call to the prescriber. Rarely, breathing gets worse right after a dose instead of better (called paradoxical bronchospasm). If that happens, use the rescue inhaler, stop Breo and contact the prescriber right away. Swelling of the face, lips, throat or tongue, or hives with trouble breathing after a dose, can be a severe allergic reaction and needs emergency care.
Do not use Breo alongside another medicine that contains a LABA, such as salmeterol (in Advair and Serevent) or formoterol (in Symbicort and Dulera). Doubling up on this type of medicine raises the risk of heart rhythm problems and other serious effects. People with a severe milk protein allergy should not use Breo, because the powder contains lactose that can carry traces of milk protein. Some medicines need extra caution or a change in plan. Ketoconazole (an antifungal medicine) and other drugs that strongly slow the body's breakdown of medicines can raise the levels of both ingredients. Beta-blockers (heart and blood pressure medicines such as propranolol) can blunt Breo's effect and may tighten the airways. Certain older antidepressants (MAO inhibitors and tricyclics) and other drugs that affect heart rhythm can strengthen vilanterol's effects on the heart, and water pills such as furosemide or hydrochlorothiazide can add to the risk of low potassium. Because Breo contains a steroid, long-term use is linked to thinning bones, cataracts and glaucoma, and it can slow growth in children, so the lowest dose that controls symptoms is preferred. Anyone who has not had chickenpox or measles, or been vaccinated, should tell their prescriber about an exposure, since these infections can be more severe in people using steroids. People switching from steroid tablets such as prednisone to Breo need a slow, supervised taper: the body's own steroid production can take months to recover, and that gap can be dangerous during an illness, injury or surgery. Heart disease, high blood pressure, seizures, an overactive thyroid and diabetes also deserve discussion before starting, and anyone pregnant or planning pregnancy should talk with the prescriber, since well-controlled asthma matters for both parent and baby.
Some people feel easier breathing on the first day, since airway opening can begin within about 15 minutes, but the steroid's effect on inflammation builds over days to weeks. The main goal is fewer symptoms day to day and fewer flare-ups over time; in COPD trials, Breo lowered the yearly rate of moderate to severe flare-ups compared with vilanterol alone, though it did not lengthen survival. Breo controls asthma and COPD but does not cure them, so it is usually continued even when you feel well, and stopping it without a plan can let symptoms return. Follow-up visits review symptoms, rescue inhaler use and inhaler technique, and in children include regular height checks; long-term users may be advised to have eye exams. Needing the rescue inhaler more often than usual, or finding it works less well, is a sign that the condition is getting worse and needs prompt contact with the care team. If breathing becomes severely difficult and the rescue inhaler does not relieve it, get emergency help.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Breo Ellipta (Fluticasone Furoate / Vilanterol), what you've noticed, or ask the community a question.